التفاصيل البيبلوغرافية
| العنوان: |
LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study |
| المؤلفون: |
Powles, T.B., Chistyakov, V., Beliakouski, V., Semenov, A., Everaert, E., Baranau, Y., Moreno, V., Perez Valderrama, B., Vano, Y., Del Conte, G., Loriot, Y., Kang, T.W., Tammaro, M., O'Hagan, A., Hosseini, M., Triantos, S., Chhabra, H., Santiago-Walker, A., Siefker-Radtke, A.O. |
| المصدر: |
In Annals of Oncology September 2021 32 Supplement 5:S1303-S1303 |
| قاعدة البيانات: |
ScienceDirect |
